Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes

Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction (HFpEF) without diabetes. The results were presented at the American Heart Association (AHA) Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571873-en) on November 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)